See more : Okaya Electric Industries Co., Ltd. (6926.T) Income Statement Analysis – Financial Results
Complete financial analysis of ArriVent BioPharma, Inc. Common Stock (AVBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ArriVent BioPharma, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Gen 2 Technologies Inc. (MNIZ) Income Statement Analysis – Financial Results
- Shizuoka Gas Co., Ltd. (9543.T) Income Statement Analysis – Financial Results
- Imerys S.A. (IMYSY) Income Statement Analysis – Financial Results
- Charter Hall Retail REIT (CQR.AX) Income Statement Analysis – Financial Results
- GIIR Inc. (035000.KS) Income Statement Analysis – Financial Results
ArriVent BioPharma, Inc. Common Stock (AVBP)
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.88M | 30.43M | 6.43M |
| General & Administrative | 9.71M | 6.47M | 3.02M |
| Selling & Marketing | 0.00 | 0.00 | -754.00K |
| SG&A | 9.71M | 6.47M | 2.26M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 74.59M | 36.91M | 8.70M |
| Cost & Expenses | 74.59M | 36.91M | 8.70M |
| Interest Income | 5.26M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 36.91M | 11.59M |
| EBITDA | -74.59M | -36.91M | -51.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -74.59M | -36.91M | -8.70M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.26M | 0.00 | -60.11M |
| Income Before Tax | -69.33M | -36.91M | -51.61M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -36.91M | -11.59M |
| Net Income | -69.33M | -36.91M | -51.61M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -2.17 | -1.10 | -1.54 |
| EPS Diluted | -2.17 | -1.10 | -1.54 |
| Weighted Avg Shares Out | 31.96M | 33.49M | 33.49M |
| Weighted Avg Shares Out (Dil) | 31.96M | 33.49M | 33.49M |
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
ArriVent BioPharma Reports First Quarter 2024 Financial Results
ArriVent Appoints Kristine Peterson to its Board of Directors
Source: https://incomestatements.info
Category: Stock Reports